(OTCBB: LGDI), (OTCBB: BMOD), (OTC:PGSVY), (OTCBB:MIVT).

Turning Pennies into dollars: (OTCBB: LGDI), (OTCBB: BMOD), (OTC:PGSVY), (OTCBB:MIVT).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://lgdi.realpennies.com

(OTCBB:LGDI) Legend International Holdings, Inc.

Legend International Holdings Announces Long Term Off-take Agreement for Phosphate Rock With India's Largest Fertilizer Enterprise

LAST $3.92 USD

Monday May 5, 6:00 am ET

MELBOURNE, Australia-Legend International Holdings, Inc , with phosphate projects in the State of Queensland, Australia, announces that it has entered into a long term off-take and supply agreement for a minimum of 3 million tons annually of concentrated rock phosphate from its Lady Annie project in Queensland, Australia, with Indian Farmers Fertilizer Cooperative Limited . Legend and IFFCO have decided to pursue the Project in Joint Venture, the terms of which are under discussion.

About Legend International Holdings Inc

Legend International Holdings, Inc is a mining and agriculture resource development company. The Company is principally focused on developing its phosphate deposits in the Georgina Basin in Queensland, Australia. The Company’s exploration licenses include approximately 5.2 million acres in Queensland and the Northern Territory, Australia. For further information please visit our website at www.lgdi.net.

For more info: http://bmod.realpennies.com

(OTCBB:BMOD) Biomoda, Inc.

Biomoda Appoints Three Business Leaders to Board of Directors

LAST $0.04 USD

Monday May 5, 8:00 am ET

New members will help commercialize innovative technologies for early lung cancer detection

ALBUQUERQUE, N.M., May 5 - Biomoda, Inc. , a development stage medical diagnostics company, recently announced the election of three business leaders, Maria Zannes, David Lambros, and Lewis White, to its Board of Directors. The Board Members' terms as Directors began May 1.

"We are pleased to engage these leaders' keen business expertise and apply their high levels of practical and regulatory experience in the interests of Biomoda shareholders," said John Cousins, Biomoda president. "With their involvement, Biomoda is in an ideal position to influence the future of technology for early diagnosis and treatment of lung cancer throughout the world."

With Biomoda's technology, clinicians can identify cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells glow red under fluorescent light and can be detected under a microscope. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease at more advanced stages. Biomoda's technology complements these tools by screening for signs of lung cancer at an earlier stage, ensuring that patients receive advanced tests at the appropriate time.

Earlier this year, Biomoda and the New Mexico Institute of Mining and Technology announced their partnership with the New Mexico Department of Veterans Services to conduct a $350,000 clinical study using Biomoda's proprietary testing technology for detection of early lung cancer in the state's veterans. The New Mexico state legislature recently allocated an additional $1.3 million in funding through the Interim Tobacco Settlement Committee to the clinical screening program.

Lung cancer claims more lives than any other cancer. The expected five-year survival rate for all patients diagnosed with lung cancer is 15 percent; the five-year survival rate for cases detected when the disease is still localized is 50 percent. Presently, only 16 percent of lung cancer cases are diagnosed at this early stage.

For more info: http://pgsvy.realpennies.com

(OTC:PGSVY) Petroleum Geo-Services ASA

Petroleum Geo-Services ASA Awarded the Industry's Largest Ever HD4D Campaign

LAST $27.80 USD

Monday May 5, 4:50 am ET

OSLO, Norway, May 5, 2008 - Petroleum Geo-Services ASA has been awarded by Petroleo Brasileiro S.A. a contract to undertake the largest High Density 4D marine seismic survey campaign ever in the industry, based on a tendered contract value of US$251 million.

President & CEO Jon Erik Reinhardsen in PGS states in a comment, ``This contract is an important strategic milestone to PGS, as we are providing the most sophisticated technology in the business, with the newest vessel in the industry, in the area where the worlds most significant recent discovery is made.''

The award is comprised of a ``Firm Program'' of five surveys, totaling 4,945 square kilometers and an ``Alternative Program'' of up to an additional 120 days of data acquisition. The Campos, Santos and Espirito Santo Basin surveys are scheduled to begin in October 2008, using PGS' latest state-of-the-art vessel, the Ramform Sovereign, which was christened in Alesund, Norway on March 12, 2008. The current estimated contract value to PGS is US$180-200 million.

High Density Time Lapsed surveys are used for reservoir management as they require optimal seismic quality in terms of resolution and repeatability. PGS' Ramform technology is tailored for these requirements due to the size and density of its streamer spreads. The Ramform Sovereign will provide Petrobras with the largest, most efficient spreads available to the industry - 18 streamers x 6,000m streamer length x 50m streamer separation or 14 streamers x 8,000m x 50m, depending on Petrobras' subsurface imaging requirements for each survey area.

According to Mike Edwards, PGS' Marine VP South America, ``PGS continues to show its long term commitment to Brazil by offering its most recent ultra-high capacity vessel for this exciting, long term Petrobras campaign. The Ramform Sovereign will reduce the data acquisition time required by standard configurations. This will decrease Petrobras' commercial exposure and enable them to begin interpreting the final product much, much sooner than previously expected.''

``PGS has shown tremendous commitment to Brazil. By offering the latest Ramform technology PGS and Petrobras will be able to take yet another step in our ongoing technological cooperation. The Ramform Sovereign is a superb choice from business and technical perspectives as she is the most advanced seismic vessel available in the industry recently,'' quoted Mario Carminatti, head of Petrobras' Exploration Department.

Petroleum Geo-Services is a focused geophysical company providing a broad range of seismic and reservoir services, including acquisition, processing, interpretation, and field evaluation. The company also possesses the world's most extensive multi-client data library. PGS operates on a worldwide basis with headquarters at Lysaker, Norway.

For more info: http://mivt.realpennies.com

(OTCBB:MIVT) MIV Therapeutics Inc.

MIV'S VESTAsync Polymer-Free Drug-Eluting Stent to Be Highlighted at Several Presentations at EuroPCR

LAST $0.24 USD

Monday May 5, 8:00 am ET

ATLANTA, GA-May 5, 2008 - MIV Therapeutics, Inc. , a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, recently announced that its VESTAsync™ polymer-free nanoscale microporous hydroxyapatite drug-eluting stent will be included in several presentations at EuroPCR08 in Barcelona. EuroPCR is the official congress of the European Association for Percutaneous Cardiovascular Interventions. The congress is being held from May 13th to 16th.

Dr. Mark Landy, president and chief executive officer of MIV will make a presentation at the Innovative and Emerging Technologies session entitled "A Novel Polymer Free Hydroxyapatite-Based Drug Delivery Stent" at which he will discuss the excellent nine-month data from the VESTAsync first-in-man clinical study first presented in March at the American Cardiology Congress. Dr. Landy's presentation will be given on Thursday, May 15th at 2:19 p.m. local time.

MIV's technology will also be featured at the session called "Glimpse Into the Future: New Drug-Eluting Stents" on May 15th beginning at 1:30 p.m. local time. The session will be chaired by Professor Patrick W. Serruys, Professor of Interventional Cardiology at the Interuniversity Cardiological Institute of the Netherlands and the Erasmus University and co-chaired by Dr. Andrea Abizaid of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil and will feature live cases and presentations.

"We are excited to continue to receive the recognition of our progress in developing a potentially safer, and possibly more effective drug-eluting stent, with the prospect of rejuvenating the worldwide drug-eluting stent market and increasing stent usage," commented Dr. Landy. "The inclusion of our technology in such a large and respected meeting of medical practitioners world-wide suggests to us that the interest in drug-eluting stents remains very robust."

About MIV Therapeutics

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite , an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used recently as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIV Therapeutics has a Collaborative Research Agreement with the University of British Columbia and has received a government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program. Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization. MIV's intellectual property portfolio includes patents held by the University of British Columbia and exclusively licensed to MIV. Key patent applications filed simultaneously in various countries around the world further protect the commercial exclusivity of MIV's inventions in the global marketplace. For more information, please visit www.mivtherapeutics.com.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

Sponsored by: http://www.isthemarketopen.com

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com